Tabletop patient monitor EndoPAT®️

cardiac outputintensive carevascular diagnostic

What if you could identify high risk patients at the earliest stage of their cardiovascular disease - would you treat them differently? Itamar Medical’s EndoPAT – the only FDA-cleared test for the non-invasive assessment of Endothelial Dysfunction (arterial health); clinically proven by leading cardiologists through prestigious peer-reviewed studies as a valuable tool in cardiovascular risk stratification beyond commonly used tests. PAT®️ technology is a non-invasive window to the cardiovascular system and autonomic nervous system. Peripheral Arterial Tone (PAT®️) signal is a proprietary technology used for non-invasively measuring arterial tone changes in peripheral arterial beds. PAT®️ technology is a non-invasive window to the cardiovascular system and autonomic nervous system. Peripheral Arterial Tone (PAT®️) signal is a proprietary technology used for non-invasively measuring arterial tone changes in peripheral arterial beds. The unique feature of the PAT®️ bio-sensors is that they impart a uniform sub-diastolic pressure field to the distal two-thirds of the fingers including their tips. Endothelial Dysfunction For more than a decade endothelial dysfunction has been recognized by the medical community as the critical junction between cardiovascular disease risk factors and clinical disease. It is the earliest detectable stage of cardiovascular disease. Furthermore, it is treatable, and unlike the atherosclerotic plaque that it causes, it is even reversible.